-
-
-
-
-
Stem Cell Therapy: 5 Major Challenges
Biotech
Explore the five major challenges in stem cell therapy, including sourcing, immune response, functional heterogeneity, post-transplant viability, and targeted delivery. Learn how these affect clinical outcomes.
-
BioNTech Acquires CureVac in $1.25B mRNA Deal
BioNTech
BioNTech acquires CureVac in a $1.25 billion all-stock deal, expanding its mRNA cancer therapy pipeline and resolving ongoing litigation. The acquisition strengthens BioNTech’s oncology strategy and manufacturing capabilities.
-
Bristol Myers Squibb Bets on ACP3 in $1.35B Deal
BMS
Bristol Myers Squibb teams up with Philochem in a $1.35B radiopharma deal to develop OncoACP3, a novel prostate cancer therapy targeting ACP3, offering a potential alternative to PSMA-focused treatments.
-
-
-
灵宝市|
娄烦县|
花莲市|
浪卡子县|
云龙县|
华安县|
卢龙县|
美姑县|
濉溪县|
蓝田县|
南康市|
洛川县|
嵊泗县|
仲巴县|
赣榆县|
灵山县|
山西省|
吴川市|
阿勒泰市|
海安县|
罗江县|
库尔勒市|
临海市|
宁陵县|
色达县|
中西区|
嫩江县|
龙南县|
卢氏县|
天峨县|
昭通市|
达日县|
秀山|
友谊县|
高唐县|
炎陵县|
连平县|
武宣县|
白玉县|
古浪县|
兴和县|